glp 1 agonist shortage The GLP-1 boom created one of the strangest health stories of the decade. Drugs built for diabetes and obesity became pop-culture products, then supply shortages opened the door to falsified versions. WHO An Ongoing Crisis: Semaglutide Shortage
Description
Ozempic and Mounjaro: What Sets Them Apart Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two front-runners fueling the GLP-1 Revolution
DPP-4 (dipeptidyl peptidase-4) inhibitors (or gliptins) represent a class of oral anti-hyperglycemic agents that inhibit the enzyme DPP-4, thus augmenting the biological activity of the incretin hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) and restoring many of the pathophysiological problems of diabetes
[DOI] [PubMed] [Google Scholar] 34.Mroz P.A., Finan B., Gelfanov V., Yang B., Tschop M.H., DiMarchi R.D., Perez-Tilve D
PMID: 21980072
Additionally, the currently approved GLP-1 RA for obesity treatment are in injectable form and some people may be reluctant to consider injectable treatments [15]
Furthermore, the 5 mg, 10 mg, and 15 mg doses exhibited superior weight loss and glycemic control relative to dulaglutide (1.5 mg), while maintaining an acceptable safety and tolerability profile
